We evaluated the role of deferasirox therapeutic drug monitoring in order to avoid toxicity or treatment failure. Plasma concentrations, measured between two consecutive liver iron determinations, were determined at the end of dosing interval. Fifty-four β-thalassemic adult patients were enrolled: 50% were males; median age was 32.3 years (IQR 19.1-41.7 years) and median body mass index was 22.25 kg/m2 (IQR 20.24-23.75 kg/m2 ). The mean deferasirox dose was 28.6 ± 6.3 mg/kg/d and mean plasma concentration was 17.3 ± 16.8 μg/mL. Drug levels showed lower results in males. Deferasirox concentration was significantly correlated with serum creatinine levels (P = .01) and serum ferritin (P < .0001). The assessment of deferasirox therapeutic drug monitoring could help clinicians to predict patient responses and to optimize the therapy.

Clinical relevance of deferasirox trough levels in β-thalassemia patients

Allegra, Sarah
Co-first
;
Massano, Davide
Co-first
;
De Francia, Silvia;Longo, Filomena;Piccione, Francesca;Pirro, Elisa;Cusato, Jessica;D'Avolio, Antonio
Co-last
;
Piga, Antonio
Co-last
2018

Abstract

We evaluated the role of deferasirox therapeutic drug monitoring in order to avoid toxicity or treatment failure. Plasma concentrations, measured between two consecutive liver iron determinations, were determined at the end of dosing interval. Fifty-four β-thalassemic adult patients were enrolled: 50% were males; median age was 32.3 years (IQR 19.1-41.7 years) and median body mass index was 22.25 kg/m2 (IQR 20.24-23.75 kg/m2 ). The mean deferasirox dose was 28.6 ± 6.3 mg/kg/d and mean plasma concentration was 17.3 ± 16.8 μg/mL. Drug levels showed lower results in males. Deferasirox concentration was significantly correlated with serum creatinine levels (P = .01) and serum ferritin (P < .0001). The assessment of deferasirox therapeutic drug monitoring could help clinicians to predict patient responses and to optimize the therapy.
45
2
213
216
creatinine; ferritin; iron overload; therapeutic drug monitoring; β-thalassemia
Allegra, Sarah; Massano, Davide; De Francia, Silvia; Longo, Filomena; Piccione, Francesca; Pirro, Elisa; Cusato, Jessica; D'Avolio, Antonio; Piga, Antonio
File in questo prodotto:
File Dimensione Formato  
Allegra_et_al-2018-Clinical_and_Experimental_Pharmacology_and_Physiology.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 295.93 kB
Formato Adobe PDF
295.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1660053
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact